AC
UTHR icon

Aaron Cowen’s United Therapeutics UTHR Stock Holding History

Aaron Cowen’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,500
Closed -$3.65M – 108
2025
Q4 		$3.65M Hold
7,500
– – 0.07% 71
2025
Q3 		$3.14M Buy
+7,500
New +$2.52M 0.08% 71
2024
Q1 		– Sell
-1,360
Closed -$299K – 113
2023
Q4 		$299K Hold
1,360
– – 0.01% 86
2023
Q3 		$307K Hold
1,360
– – 0.02% 86
2023
Q2 		$300K Hold
1,360
– – 0.02% 95
2023
Q1 		$305K Buy
+1,360
New +$335K 0.01% 91

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Aaron Cowen's UTHR Position: Q1 2026 in Review

Aaron Cowen sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 7,500 shares — an estimated $3.65M sold.

Aaron Cowen first reported a position in UTHR in Q1 2023 and held it in 6 quarters. The position peaked at $3.65M in Q4 2025. 853 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Aaron Cowen reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aaron Cowen sold 7,500 United Therapeutics shares in Q1 2026, an estimated $3.65M.
  • Aaron Cowen first reported a position in United Therapeutics in Q1 2023 and held it in 6 quarters.
  • Aaron Cowen's United Therapeutics position peaked at $3.65M in Q4 2025.
  • 853 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.